Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 2/20 | 0.40 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.40 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.40 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.40 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.40 |
| ▸ | RIPK1 | Q13546 | 2/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.38 |
| ▸ | CCNC | P24863 | 1/20 | 0.38 |
| ▸ | CDK8 | P49336 | 1/20 | 0.38 |
| ▸ | CPT1A | P50416 | 4/20 | 0.37 |
| ▸ | CPT2 | P23786 | 3/20 | 0.37 |
| ▸ | CPT1B | Q92523 | 3/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14610878 | 0.88 | RIPK1 (0.46) | RIPK1NPSR1CCNCCDK8 | |
| SCHEMBL14610831 | 0.87 | ROCK2 (0.42) | ROCK2RIPK1CCNCCDK8CPT1A | |
| SCHEMBL14569581 | 0.83 | ROCK2 (0.44) | ROCK2RIPK1CCNCCDK8 | |
| SCHEMBL20905412 | 0.79 | RIPK1 (0.59) | RIPK1CCNCCDK8 | |
| SCHEMBL14611259 | 0.75 | RIPK1 (0.44) | RIPK1 | |
| SCHEMBL14557706 | 0.74 | HRH3 (0.46) | RIPK1NPSR1HRH3 | |
| SCHEMBL14569542 | 0.74 | RIPK1 (0.49) | RIPK1HRH3CCNCCDK8 | |
| SCHEMBL14557696 | 0.73 | EPHX2 (0.43) | RIPK1 | |
| SCHEMBL14557693 | 0.73 | KDM4E (0.41) | ROCK2RIPK1NPSR1 | |
| SCHEMBL14557747 | 0.71 | NPSR1 (0.48) | NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070054909-A1 | VLA-4 inhibitor compounds | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-03-08 | — | — | US | disclosed |
| US-7179819-B2 | VLA-4 inhibitor compounds | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-02-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070054909-A1 | VLA-4 inhibitor compounds | VCAM1, ITGB4, ICAM1 | ROCK2 1291/4885GRIN2D 3321/4885GRIN2A 3037/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.